Mycoplasma Patents (Class 424/264.1)
  • Patent number: 10870669
    Abstract: The present invention provides a novel glyceroglycolipid produced by Mycoplasma pneumoniae. The glyceroglycolipid can be used as a diagnostic marker for a disease caused by Mycoplasma pneumoniae.
    Type: Grant
    Filed: December 27, 2018
    Date of Patent: December 22, 2020
    Assignee: M BIO TECHNOLOGY INC.
    Inventors: Kazuhiro Matsuda, Yuko Shingu
  • Patent number: 9649369
    Abstract: This invention provides a multivalent immunogenic composition including a soluble portion of a Mycoplasma hyopneumoniae (M. hyo) whole cell preparation; and a porcine circovirus type 2 (PCV2) antigen, wherein the soluble portion of the M. hyo preparation is substantially free of both (i) IgG and (ii) immunocomplexes comprised of antigen bound to immunoglobulin.
    Type: Grant
    Filed: May 14, 2015
    Date of Patent: May 16, 2017
    Assignee: Zoetis Services LLC
    Inventors: Gregory P. Nitzel, Jeffrey E. Galvin, John Keith Garrett, James R. Kulawik, II, Tracy L. Ricker, Megan Marie Smutzer
  • Patent number: 9650601
    Abstract: This invention provides a trivalent immunogenic composition including a soluble portion of a Mycoplasma hyopneumoniae (M.hyo) whole cell preparation; a porcine circovirus type 2 (PCV2) antigen; and a PRRS virus antigen, wherein the soluble portion of the M.hyo preparation is substantially free of both (i) IgG and (ii) immunocomplexes comprised of antigen bound to immunoglobulin.
    Type: Grant
    Filed: May 14, 2015
    Date of Patent: May 16, 2017
    Assignee: Zoetis Services LLC
    Inventors: Gregory P. Nitzel, Jeffrey E. Galvin, John Keith Garrett, James R. Kulawik, II, Tracy L. Ricker, Megan Marie Smutzer
  • Patent number: 9650600
    Abstract: This invention provides an immunogenic composition including a soluble portion of a Mycoplasma hyopneumoniae (M.hyo) whole cell preparation, wherein the soluble portion of the M.hyo preparation is substantially free of both (i) IgG and (ii) immunocomplexes comprised of antigen bound to immunoglobulin.
    Type: Grant
    Filed: May 14, 2015
    Date of Patent: May 16, 2017
    Assignee: Zoetis Services LLC
    Inventors: Jeffrey E. Galvin, Gregory P. Nitzel, John Keith Garrett, James R. Kulawik, II, Tracy L. Ricker, Megan Marie Smutzer
  • Patent number: 9056909
    Abstract: Provided are immunogenic and vaccine compositions and methods for their preparation and use, which compositions are effective in protecting against, minimizing the severity of, preventing, and/or ameliorating M. hyopneumoniae infection. Administration to an animal of one or two doses of an adjuvanted live avirulent M. hyopneumoniae composition disclosed herein is effective in providing immunity to the animal and protection from infection with a virulent strain of M. hyopneumoniae thereby reducing the severity of and/or preventing disease caused by one or more virulent strain of M. hyopneumoniae. Also provided are compositions, which further comprise one or more antigen such as, for example, one or more live bacteria, bacterin, toxoid, and/or virus and/or viral antigen. Exemplified are immunogenic compositions, comprising an adjuvanted live avirulent M.
    Type: Grant
    Filed: November 5, 2008
    Date of Patent: June 16, 2015
    Assignee: Zoetis Services LLC
    Inventors: Hsien-Jue Chu, Zhichang Xu, Wumin Li, Nicole Rae Gibson
  • Publication number: 20150086590
    Abstract: A vaccine composition for birds comprising as an active ingredient a structure containing O-antigen derived from Gram-negative bacteria, provided that said structure does not contain a whole cell, and a process for preparing the same are provided. By using a structure containing O-antigen (e.g. lipopolysaccharide) derived from Gram-negative bacteria as an active ingredient in accordance with the present invention, alleviation of inoculation reaction and reduction in an amount of injection are attained as compared to the conventional whole-cells vaccine to thereby allow for the increase in the number of other antigens to be mixed therewith.
    Type: Application
    Filed: February 19, 2013
    Publication date: March 26, 2015
    Applicant: THE CHEMO-SERO-THERAPEUTIC RESEARCH INSTITUTE
    Inventors: Ryuichi Sakamoto, Masashi Sakaguchi
  • Publication number: 20150086587
    Abstract: Oil-based adjuvant emulsions, immunogenic compositions, and methods of using the same to elicit immunological responses in a subject are provided. The oil-based adjuvants comprise a plant-derived surfactant, such as gum arabic, an aqueous component, and an oil. The adjuvant emulsions can be used to potentiate the immunological effects of active agents, including antigens derived from various pathogens and/or toxins. Immunogenic compositions comprising the adjuvant emulsions and various active agents are also provided, along with vaccine systems for therapeutic or prophylactic treatment of a subject using these adjuvants.
    Type: Application
    Filed: March 28, 2013
    Publication date: March 26, 2015
    Inventors: Jishu Shi, Loretta Pappan, Amy Beckley, Qixin Zhong
  • Patent number: 8940309
    Abstract: The present invention provides a one phase, aqueous vaccine composition for immunizing an animal against infection by Mycoplasma hyopneumoniae, comprising: an immunizing amount of a Mycoplasma hyopneumoniae bacterin, an acrylic acid polymer in the concentration range between 0.8 and 1.2 mg/ml, and a pharmaceutically acceptable carrier, and substantially no oil. It is especially useful for immunizing a pig against infection by Mycoplasma hyopneumoniae for at least 20 weeks after a single administration, which effective immunity is reached within 4 weeks after vaccination.
    Type: Grant
    Filed: September 4, 2014
    Date of Patent: January 27, 2015
    Assignee: Boehringer Ingelheim Vetmedica, Inc.
    Inventors: William Charles Ohnesorge, Isabelle Freiin Von Richthofen, Marika Christine Genzow, Martina Von Freyburg, Carola Kissel, Luc-Etienne Fabry, Knut Elbers, Kathleen Kwan Young Park
  • Publication number: 20140370058
    Abstract: The present invention provides a one phase, aqueous vaccine composition for immunizing an animal against infection by Mycoplasma hyopneumoniae, comprising: an immunizing amount of a Mycoplasma hyopneumoniae bacterin, an acrylic acid polymer in the concentration range between 0.8 and 1.2 mg/ml, and a pharmaceutically acceptable carrier, and substantially no oil. It is especially useful for immunizing a pig against infection by Mycoplasma hyopneumoniae for at least 20 weeks after a single administration, which effective immunity is reached within 4 weeks after vaccination.
    Type: Application
    Filed: September 4, 2014
    Publication date: December 18, 2014
    Applicant: BOEHRINGER INGELHEIM VETMEDICA GMBH
    Inventors: William Charles OHNESORGE, Isabelle FREIIN VON RICHTHOFEN, Marika Christine GENZOW, Martina VON FREYBURG, Carola KISSEL, Luc-Etienne FABRY, Knut ELBERS, Kathleen Kwan Young PARK
  • Patent number: 8906630
    Abstract: The present invention encompasses methods, assays and kits for the detection of pathogenic bacteria in a patient and for the differential diagnosis of pulmonary diseases associated with pathogenic bacteria from pulmonary diseases not associated with pathogenic bacteria.
    Type: Grant
    Filed: February 25, 2005
    Date of Patent: December 9, 2014
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Jeffrey N. Weiser, Jane M. Gould
  • Patent number: 8900623
    Abstract: The present invention is directed to a composition, kit and method for delivering a soft flowable gel to a flock of poultry in barns, but can also be used in hatcheries or free range farms, for treating poultry with a therapeutic agent. The soft flowable gel comprises water, a gelling agent, a therapeutic agent and between about 0.05% and 0.15% xanthan gum.
    Type: Grant
    Filed: July 27, 2010
    Date of Patent: December 2, 2014
    Assignee: Vetech Laboratories Inc.
    Inventor: Eng-Hong Lee
  • Patent number: 8852613
    Abstract: The present invention provides a one phase, aqueous vaccine composition for immunizing an animal against infection by Mycoplasma hyopneumoniae, comprising: an immunizing amount of a Mycoplasma hyopneumoniae bacterin, an acrylic acid polymer in the concentration range between 0.8 and 1.2 mg/ml, and a pharmaceutically acceptable carrier, and substantially no oil. It is especially useful for immunizing a pig against infection by Mycoplasma hyopneumoniae for at least 20 weeks after a single administration, which effective immunity is reached within 4 weeks after vaccination.
    Type: Grant
    Filed: April 24, 2013
    Date of Patent: October 7, 2014
    Assignee: Boehringer Ingelheim Vetmedica, Inc.
    Inventors: William Charles Ohnesorge, Isabelle Freiin von Richthofen, Marika Christine Genzow, Martina von Freyburg, Carola Kissel, Luc-Etienne Fabry, Knut Elbers, Kathleen Kwan Young Park
  • Patent number: 8815255
    Abstract: The present invention relates to combination vaccines and/or the combined use of immunogenic compositions for the treatment and/or prophylaxis of cattle against microbiological infections, wherein the infections are caused by M. bovis and at least one further cattle relevant pathogen. The combination vaccine as described herein comprises at least one M. bovis antigen, preferably the attenuated, avirulent M. bovis as provided herewith and one or more further immunologically active components effective for the treatment and/or prophylaxis of infections caused by a further pathogen of cattle.
    Type: Grant
    Filed: October 22, 2009
    Date of Patent: August 26, 2014
    Assignee: Boehringer Ingelheim Vetmedica, Inc.
    Inventors: Michael Beck, Phillip Wayne Hayes, Jeffrey P. Knittel
  • Publication number: 20140205633
    Abstract: The present invention relates to immunostimulatory oligodeoxynucleotides, vectors and vaccines comprising such oligodeoxynucleotides, to their use as a medicament, to their use in preventing or combating infectious disease, to methods for the detection of such oligodeoxynucleotides and to cells to be used in these method.
    Type: Application
    Filed: December 29, 2011
    Publication date: July 24, 2014
    Inventors: Carla Christina Schrier, Thomas Simon Ilg
  • Publication number: 20140193457
    Abstract: The present invention relates to immunostimulatory oligodeoxynucleotides, vectors and vaccines comprising such oligodeoxynucleotides, to their use as a medicament, to their use in preventing or combating infectious disease and to methods for the detection of such oligodeoxynucleotides.
    Type: Application
    Filed: May 25, 2012
    Publication date: July 10, 2014
    Inventors: Carla Christina Schrier, Simon ILG
  • Publication number: 20140141041
    Abstract: The present invention shows that intranasal administration of E1/E3-defective adenovirus particles may confer rapid and broad protection against viral and bacterial pathogens in a variety of disease settings. Protective responses lasted for many weeks in a single-dose regimen in animal models. When a pathogen-derived antigen gene was inserted into the E1/E3-defective adenovirus genome, the antigen-induced protective immunity against the specific pathogen was elicited before the adenovirus-mediated protective response declined away, thus conferring rapid, prolonged, and seamless protection against pathogens. In addition to E1/E3-defective adenovirus, other bioengineered non-replicating vectors encoding pathogen-derived antigens may also be developed into a new generation of rapid and prolonged immunologic-therapeutic (RAPIT).
    Type: Application
    Filed: December 30, 2013
    Publication date: May 22, 2014
    Applicant: VAXIN INC.
    Inventor: De-Chu C. Tang
  • Patent number: 8668912
    Abstract: The present invention provides a formulation that prevents virulent Mycoplasma galHsepticum infection in birds of the order GaIHf ormes. The formulation comprises live Mycoplasma galHsepticum strain K5831 or derivatives thereof in a pharmaceutically acceptable carrier. A vaccine that prevents virulent Mycoplasma galHsepticum infection in birds of the order Galliformes is also presented. Methods for administering the formulation and vaccine are also presented.
    Type: Grant
    Filed: January 22, 2010
    Date of Patent: March 11, 2014
    Assignee: University of Georgia Research Foundation, Inc.
    Inventors: Stanley H. Kleven, Naola M. Ferguson
  • Publication number: 20140056940
    Abstract: This invention relates to adjuvant formulations comprising various combinations of triterpenoids, sterols, immunomodulators, polymers, and Th2 stimulators; methods for making the adjuvant compositions; and the use of the adjuvant formulations in immunogenic and vaccine compositions with different antigens. This invention further relates to the use of the formulations in the treatment of animals.
    Type: Application
    Filed: August 29, 2013
    Publication date: February 27, 2014
    Inventors: Paul Joseph Dominowski, Ramasamy Mannar Mannan, Richard Lee Krebs, James Richard Thompson, Tedd Alan Childers, Mary Kathryn Olsen, Robert John Yancey, JR., Risini Dhammika Weeratna, Shucheng Zhang, Cedo Martin Bagi
  • Patent number: 8652481
    Abstract: The present invention relates to new attenuated M. bovis bacteria strains. Moreover, the present invention also provides immunogenic compositions comprising live bacteria of an of those attenuated M. bovis bacteria strain, their manufacture and use for the treatment and prophylaxis of M. bovis infections.
    Type: Grant
    Filed: October 29, 2008
    Date of Patent: February 18, 2014
    Assignee: Boehringer Ingelheim Vetmedica, Inc.
    Inventors: Michael Beck, Jeffrey Knittel
  • Publication number: 20140037716
    Abstract: The present invention relates to immunogenic compositions for modulating the immune system, comprising a therapeutically effective quantity of two or more immuno-active antigenic agents with pathogen-associated molecular patterns (PAMPs) and/or danger-associated molecular patterns (DAMPs) and one or more physiologically acceptable carriers, excipients, diluents or solvents. The immunogenic compositions according to the present invention are used for producing medicaments for preventing and/or treating, and for preventing and/or treating infectious diseases, auto-immune diseases, allergic diseases, inflammation, arthritis, inflammatory diseases, transplant rejection, affections caused by vascular disorders, diseases caused by haemorrhagic or ischaemic cardiovascular accidents, ischaemia, heart attack and haemorrhagia leading to tissue destruction, heart, kidney, respiratory or liver insufficiency, cancer, malign and benign tumours and neoplasia.
    Type: Application
    Filed: March 19, 2012
    Publication date: February 6, 2014
    Inventor: Alexandre Eduardo Nowill
  • Patent number: 8586059
    Abstract: This document provides live non-pathogenic M. bovis bacteria and compositions containing live non-pathogenic M. bovis bacteria. This document also provides methods of using live non-pathogenic M. bovis bacteria to immunize cattle against infectious diseases (e.g., diseases caused by M. bovis bacteria). In addition, methods and materials that can be used to generate live non-pathogenic M. bovis bacteria are provided.
    Type: Grant
    Filed: June 3, 2009
    Date of Patent: November 19, 2013
    Assignees: Iowa State University Research Foundation, Inc., Biotechnology Research and Development Corporation
    Inventors: Ricardo Rosenbusch, Nakhyung Lee
  • Publication number: 20130302373
    Abstract: The present invention provides live, attenuated Mycoplasma gallisepticum bacteria that exhibit reduced expression of a protein identified as MGA_0621. In certain embodiments, the attenuated bacteria may additionally exhibit reduced expression of one or more proteins selected from the group consisting of pyruvate dehydrogenase, phosphopyruvate hydratase, 2-deoxyribose-5-phosphate aldolase, and ribosomal protein L35, relative to a wild-type M. gallisepticum bacterium. Also provided are vaccines and vaccination methods involving the use of the live, attenuated M. gallisepticum bacteria, and methods for making live attenuated M. gallisepticum bacteria. An exemplary live, attenuated strain of M. gallisepticum is provided, designated MGx+47, which was shown by proteomics analysis to exhibit significantly reduced expression of MGA_0621, and was shown to be safe and effective when administered as a vaccine against M. gallisepticum infection in chickens.
    Type: Application
    Filed: July 25, 2013
    Publication date: November 14, 2013
    Inventors: Mahesh KUMAR, Muhammad Ayub KHAN
  • Publication number: 20130266601
    Abstract: This invention provides an immunogenic composition including a soluble portion of a Mycoplasma hyopneumoniae (M.hyo) whole cell preparation, wherein the soluble portion of the M.hyo preparation is substantially free of both (i) IgG and (ii) immunocomplexes comprised of antigen bound to immunoglobulin.
    Type: Application
    Filed: March 26, 2013
    Publication date: October 10, 2013
    Applicant: Zoetis LLC
    Inventors: Jeffrey E. Galvin, Gregory P. Nitzel, John Keith Garrett, James R. Kulawik, II, Tracy L. Ricker, Megan Marie Smutzer
  • Publication number: 20130243819
    Abstract: The present invention provides a method for identifying or generating an attenuated mycoplasma bacterium, which bacterium comprises a mutation in at least one gene as listed and use of the bacterium in a vaccine for eliciting protective immunity against mycoplasma or for detecting infection by said bacterium.
    Type: Application
    Filed: May 19, 2011
    Publication date: September 19, 2013
    Applicant: Bioproperties Pty Ltd
    Inventors: Rima Youil, Youssef Abs El-Osta
  • Publication number: 20130230558
    Abstract: The present invention provides a one phase, aqueous vaccine composition for immunizing an animal against infection by Mycoplasma hyopneumoniae, comprising: an immunizing amount of a Mycoplasma hyopneumoniae bacterin, an acrylic acid polymer in the concentration range between 0.8 and 1.2 mg/ml, and a pharmaceutically acceptable carrier, and substantially no oil. It is especially useful for immunizing a pig against infection by Mycoplasma hyopneumoniae for at least 20 weeks after a single administration, which effective immunity is reached within 4 weeks after vaccination.
    Type: Application
    Filed: April 24, 2013
    Publication date: September 5, 2013
    Applicant: BOEHRINGER INGELHEIM VETMEDICA GMBH
    Inventors: Wiliam Charles OHNESORGE, Isabelle FREIIN VON RICHTHOFEN, Marika Christine GENZOW, Martina VON FREYBURG, Carola KISSEL, Luc-Etienne FABRY, Knut ELBERS, Kathleen Kwan Young PARK
  • Patent number: 8524252
    Abstract: The present invention relates to a Mycoplasma hyopneumoniae vaccine strain comprising a mutation in at least one of the genes listed or as deposited with the National Measurements Institute (Australia) under accession number NM04/41259, which strain is temperature sensitive and attenuated, a vaccine comprising such strains and methods and uses thereof.
    Type: Grant
    Filed: May 19, 2010
    Date of Patent: September 3, 2013
    Assignees: Bioproperties Pty Ltd., The University of Melbourne
    Inventors: Rima Youil, Youssef Abs El-Osta, Glenn Browning, Phillip Markham
  • Patent number: 8444989
    Abstract: The present invention provides a one phase, aqueous vaccine composition for immunizing an animal against infection by Mycoplasma hyopneumoniae, comprising: an immunizing amount of a Mycoplasma hyopneumoniae bacterin, an acrylic acid polymer in the concentration range between 0.8 and 1.2 mg/ml, and a pharmaceutically acceptable carrier, and substantially no oil. It is especially useful for immunizing a pig against infection by Mycoplasma hyopneumoniae for at least 20 weeks after a single administration, which effective immunity is reached within 4 weeks after vaccination.
    Type: Grant
    Filed: April 14, 2009
    Date of Patent: May 21, 2013
    Assignee: Boehringer Ingelheim Vetmedica GmbH
    Inventors: Wiliam Charles Ohnesorge, Isabelle Freiin von Richthofen, Marika Genzow, Martina von Freyburg, Carola Kissel, Luc-Etienne Fabry, Knut Elbers, Kathleen Park
  • Publication number: 20130064852
    Abstract: The invention pertains to a vaccine comprising Mycoplasma hyopneumoniae antigens for intradermal application to an animal that has maternally derived antibodies directed against Mycoplasma hyopneumoniae, to actively protect the animal against a disorder arising from an infection with Mycoplasma hyopneumoniae. The invention also pertains to the manufacture of this vaccine and a method of protecting an animal by administrating this vaccine.
    Type: Application
    Filed: May 10, 2011
    Publication date: March 14, 2013
    Applicant: INTERVET INTERNATIONAL B.V.
    Inventor: Maarten Hendrik Witvliet
  • Patent number: 8367076
    Abstract: The present invention provides a novel glyceroglycolipid produced by Mycoplasma pneumoniae. The glyceroglycolipid can be used as a diagnostic marker for a disease caused by Mycoplasma pneumoniae.
    Type: Grant
    Filed: June 13, 2007
    Date of Patent: February 5, 2013
    Assignee: M Bio Technology Inc.
    Inventors: Kazuhiro Matsuda, Yuko Shingu
  • Patent number: 8298552
    Abstract: The present invention provides live, attenuated Mycoplasma gallisepticum bacteria that exhibit reduced expression of a protein identified as MGA_0621. In certain embodiments, the attenuated bacteria may additionally exhibit reduced expression of one or more proteins selected from the group consisting of pyruvate dehydrogenase, phosphopyruvate hydratase, 2-deoxyribose-5-phosphate aldolase, and ribosomal protein L35, relative to a wild-type M. gallisepticum bacterium. Also provided are vaccines and vaccination methods involving the use of the live, attenuated M. gallisepticum bacteria, and methods for making live attenuated M. gallisepticum bacteria. An exemplary live, attenuated strain of M. gallisepticum is provided, designated MGx+47, which was shown by proteomics analysis to exhibit significantly reduced expression of MGA_0621, and was shown to be safe and effective when administered as a vaccine against M. gallisepticum infection in chickens.
    Type: Grant
    Filed: March 25, 2011
    Date of Patent: October 30, 2012
    Assignee: Wyeth LLC
    Inventors: Mahesh Kumar, Muhammad Ayub Khan
  • Publication number: 20120213816
    Abstract: The invention provides an improved Mycoplasma hyopneumoniae bacterin vaccine composition, which advantageously provides immunity from infection after a single administration. The composition comprises an inactivated Mycoplasma hyopneumoniae bacterin and an adjuvant mixture, which, in combination, provide immunity from Mycoplasma hyopneumoniae infection after a single administration, and elicit an immune response specific to Mycoplasma hyopneumoniae bacterin and including cell-mediated immunity and local (secretory IgA) immunity. In a preferred embodiment, the adjuvant mixture comprises an acrylic acid polymer, most preferably CARBOPOL®, and a mixture of a metabolizable oil such as one or more unsaturated terpene hydrocarbons, preferably squalene or squalane, and a polyoxyethylene-polyoxypropylene block copolymer such as PLURONIC®. The vaccine composition may optionally include a preservative, preferably thimerosol and/or EDTA.
    Type: Application
    Filed: April 27, 2012
    Publication date: August 23, 2012
    Inventors: Hsien-Jue Chu, Wumin Li, Zhichang Xu
  • Publication number: 20120135040
    Abstract: The present invention relates to a Mycoplasma hyopneumoniae vaccine strain comprising a mutation in at least one of the genes listed or as deposited with the National Measurements Institute (Australia) under accession number NM04/41259, which strain is temperature sensitive and attenuated, a vaccine comprising such strains and methods and uses thereof.
    Type: Application
    Filed: May 19, 2010
    Publication date: May 31, 2012
    Inventors: Rima Youil, Youssef Abs El-Osta, Glenn Browning, Phillip Markham
  • Publication number: 20120093854
    Abstract: The present invention relates to combination vaccines and/or the combined use of immunogenic compositions for the treatment and/or prophylaxis of cattle against microbiological infections, wherein the infections are caused by M. bovis and at least one further cattle relevant pathogen. The combination vaccine as described herein comprises at least one M. bovis antigen, preferably the attenuated, avirulent M. bovis as provided herewith and one or more further immunologically active components effective for the treatment and/or prophylaxis of infections caused by a further pathogen of cattle.
    Type: Application
    Filed: October 22, 2009
    Publication date: April 19, 2012
    Applicant: BOEHRINGER INGELHEIM VETMEDICA, INC.
    Inventors: Michael Beck, Phillip Wayne Hayes, Jeffrey P. Knittel
  • Publication number: 20120021005
    Abstract: The present invention provides a formulation that prevents virulent Mycoplasma galHsepticum infection in birds of the order GaIHf ormes. The formulation comprises live Mycoplasma galHsepticum strain K5831 or derivatives thereof in a pharmaceutically acceptable carrier. A vaccine that prevents virulent Mycoplasma galHsepticum infection in birds of the order Galliformes is also presented. Methods for administering the formulation and vaccine are also presented.
    Type: Application
    Filed: January 22, 2010
    Publication date: January 26, 2012
    Applicant: University of Georgia Research Foundation, Inc.
    Inventors: Stanley H. Kleven, Naola M. Ferguson
  • Patent number: 8088894
    Abstract: The present invention provides a Mycoplasma pneumoniae community acquired respiratory distress syndrome (CARDS) toxin, biologically active fragments/domains of the CARDS toxin, antibodies to the CARDS toxin and nucleic acids encoding the CARDS toxin. Also provided are methods of diagnosing, treating and/or preventing infection by Mycoplasma pneumoniae using the compositions provided herein.
    Type: Grant
    Filed: November 4, 2009
    Date of Patent: January 3, 2012
    Assignee: Board of Regents, The University of Texas System
    Inventors: Joel Barry Baseman, Thirumalai Rengasamy Kannan
  • Publication number: 20110300179
    Abstract: The present invention provides a cellular vaccine for therapeutic or prophylactic treatment of a pathological condition, the vaccine comprising or consisting of a population of CD 4+ T cells modified such that they contain an antigenic component, and/or a nucleic acid molecule encoding an antigenic component thereof, wherein the T cells are (a) activated, or capable of being activated, and (b) apoptotic, or capable or being made apoptotic. The invention further provides an adjuvant composition for use in a method of vaccination, the composition comprising or consisting of a population of T cells, wherein the T cells are (a) activated, or capable of being activated, and (b) apoptotic, or capable or being made apoptotic.
    Type: Application
    Filed: November 12, 2007
    Publication date: December 8, 2011
    Inventors: Anna-Lena Spetz-Holmgren, Ulrika Johansson, Jan Andersson, Lilian Walther-Jallow
  • Patent number: 8021670
    Abstract: The present invention relates to the use of an immunogenic dose of immunogenic material of Mycoplasma hyopneumoniae and an immunogenic dose of live attenuated PRRS virus for the manufacture of a vaccine, and to a vaccine kit comprising such a vaccine.
    Type: Grant
    Filed: April 6, 2007
    Date of Patent: September 20, 2011
    Assignee: Intervet International B.V.
    Inventors: Christa Sibilla Drexler, Maarten Witvliet
  • Publication number: 20110223195
    Abstract: The invention relates to vaccine compositions comprising chitosan and a vaccine which are administered to avian species via the ocular route, and methods or programs of vaccination including use of chitosan in order to increase or enhance cell-mediated immunity in avian species and persistence of the vaccine avian tissues.
    Type: Application
    Filed: September 4, 2009
    Publication date: September 15, 2011
    Applicant: CEVA SANTE ANIMALE SA
    Inventors: Yannick Gardin, Vilmos Palya, Sylvain Comte
  • Publication number: 20110150933
    Abstract: This document provides live non-pathogenic M. bovis bacteria and compositions containing live non-pathogenic M. bovis bacteria. This document also provides methods of using live non-pathogenic M. bovis bacteria to immunize cattle against infectious diseases (e.g., diseases caused by M. bovis bacteria). In addition, methods and materials that can be used to generate live non-pathogenic M. bovis bacteria are provided.
    Type: Application
    Filed: June 3, 2009
    Publication date: June 23, 2011
    Inventors: Ricardo Rosenbusch, Nakhyung Lee
  • Patent number: 7959927
    Abstract: The invention provides an improved Mycoplasma hyopneumoniae bacterin vaccine composition, which advantageously provides immunity from infection after a single administration. The composition comprises an inactivated Mycoplasma hyopneumoniae bacterin and an adjuvant mixture, which, in combination, provide immunity from Mycoplasma hyopneumoniae infection after a single administration, and elicit an immune response specific to Mycoplasma hyopneumoniae bacterin and including cell-mediated immunity and local (secretory IgA) immunity. In a preferred embodiment, the adjuvant mixture comprises an acrylic acid polymer, most preferably CARBOPOL®, and a mixture of a metabolizable oil such as one or more unsaturated terpene hydrocarbons, preferably squalene or squalane, and a polyoxyethylene-polypropylene block copolymer such as PLURONIC®. The vaccine composition may optionally include a preservative, preferably thimerosal and/or EDTA.
    Type: Grant
    Filed: November 16, 2009
    Date of Patent: June 14, 2011
    Assignee: Wyeth LLC
    Inventors: Hsien-Jue Chu, Wumin Li, Zhichang Xu
  • Publication number: 20110129494
    Abstract: The present invention provides for a novel oil-in-water (O/W) emulsion, with increased stability in the presence of bacterial or viral suspensions, especially those concentrated and non-purified (crude extracts) or minimally purified. The emulsion of the present invention can act as vehicle for the delivery of a pharmaceutical composition comprising at least one immunogen and, in particular, an immunogen selected from the group consisting of an inactivated pathogen, an attenuated pathogen, a subunit, a recombinant expression vector, and a plasmid or combinations thereof.
    Type: Application
    Filed: September 9, 2010
    Publication date: June 2, 2011
    Inventors: Noel Joseph Francois Detraz, Guillaume Rigaut
  • Patent number: 7943153
    Abstract: The invention of novel, effective vaccines against Mycoplasma. bovis for use in cattle is described. These vaccines demonstrate no undesirable side effects and protect against M. bovis related disease, such as contagious mastitis, respiratory pneumonia, joint infections, keratoconjunctivitis and middle ear infections. The novel vaccines also lessen the effect of M. bovis infections on milk production, weight gain and animal health. Methods of diagnosing, characterizing and treating M. bovis infections as specific biotypes are also disclosed. Vaccine compositions made in accordance with the invention may be either of the attenuated or inactivated variety. Vaccines may also include antigens from other pathogens so as to provide a protective immunogenic response to diseases other than those caused by M. bovis.
    Type: Grant
    Filed: November 8, 2000
    Date of Patent: May 17, 2011
    Assignee: Biomune
    Inventors: Joan D. Leonard, Robert W. Tully
  • Publication number: 20110104207
    Abstract: The present invention relates to compounds which inhibit bacterial gyrase and pharmaceutically acceptable compositions comprising said compounds. These compounds, and compositions thereof, are useful in treating bacterial infection. Accordingly, the present invention also relates to methods for treating bacterial infections in mammals. The present invention also relates to a method for preparing these compounds.
    Type: Application
    Filed: April 16, 2010
    Publication date: May 5, 2011
    Applicant: VERTEX PHARMACEUTICALS INCORPORATED
    Inventors: Paul CHARIFSON, David DEININGER, Joseph DRUMM, Anne-Laure GRILLOT, Yusheng LIAO, Patricia OLIVER-SHAFFER, Dean STAMOS
  • Patent number: 7935356
    Abstract: The present invention provides live, attenuated Mycoplasma gallisepticum bacteria that exhibit reduced expression of a protein identified as MGA_0621. In certain embodiments, the attenuated bacteria may additionally exhibit reduced expression of one or more proteins selected from the group consisting of pyruvate dehydrogenase, phosphopyruvate hydratase, 2-deoxyribose-5-phosphate aldolase, and ribosomal protein L35, relative to a wild-type M. gallisepticum bacterium. Also provided are vaccines and vaccination methods involving the use of the live, attenuated M. gallisepticum bacteria, and methods for making live attenuated M. gallisepticum bacteria. An exemplary live, attenuated strain of M. gallisepticum is provided, designated MGx+47, which was shown by proteomics analysis to exhibit significantly reduced expression of MGA_0621, and was shown to be safe and effective when administered as a vaccine against M. gallisepticum infection in chickens.
    Type: Grant
    Filed: September 10, 2008
    Date of Patent: May 3, 2011
    Assignee: Wyeth LLC
    Inventors: Mahesh Kumar, Muhammad Ayub Khan
  • Publication number: 20110059128
    Abstract: A vaccine composition for vaccinating dogs comprising any one or more of (a) an agent capable of raising an immune response against Streptococcus equi sub species zooepidemicus in a dog, (b) an agent capable of raising an immune response against Mycoplasma cynos in a dog, and (c) an agent capable of raising an immune response against a Chlamydophila in a dog.
    Type: Application
    Filed: June 15, 2010
    Publication date: March 10, 2011
    Applicant: THE ROYAL VETERINARY COLLEGE
    Inventors: JOHN BROWNLIE, VICTORIA JANE CHALKER, KERSTIN ERLES
  • Patent number: 7858345
    Abstract: Mycoplasma hyopneumoniae polypeptides and nucleic acids, as well as nucleic acid expression vectors and host cells containing nucleic acid vectors are provided. In addition, compositions containing M. hyopneumoniae polypeptides and nucleic acids are provided for use in methods of treating swine to prevent enzootic pneumonia. Furthermore, the invention provides diagnostic tests for the detecting of M. hyopneumoniae infection in swine herds.
    Type: Grant
    Filed: July 31, 2008
    Date of Patent: December 28, 2010
    Assignees: Iowa State University Research Foundation, Inc., Department of Agriculture for and on Behalf of the State of New South Wales
    Inventors: F Chris Minion, Steven P Djordjevic
  • Patent number: 7833536
    Abstract: The present invention relates i.a. to vaccines for combating Mycoplasma infection, to mycoplasmal L-?-glycerophosphate oxidase for use in such vaccines, to the use of mycoplasmal L-?-glycerophosphate oxidase for the manufacturing of such vaccines, to methods for the preparation of such vaccines and to diagnostic tests for the discrimination of animals vaccinated with said vaccines and animals vaccinated with whole cell vaccines or animals suffering from field infection.
    Type: Grant
    Filed: July 6, 2006
    Date of Patent: November 16, 2010
    Assignee: University of Bern
    Inventors: Joachim Frey, Edy M. Vilei, Paola Pilo
  • Publication number: 20100272759
    Abstract: The present invention relates to new attenuated M. bovis bacteria strains passaged at least 110 times. Moreover, the present invention also provides immunogenic compositions comprising live bacteria of any of those attenuated M. bovis bacteria strain, their manufacture and use for the treatment and prophylaxis of M. bovis infections and combinations with other veterinary vaccines or medicaments.
    Type: Application
    Filed: April 23, 2010
    Publication date: October 28, 2010
    Applicant: BOEHRINGER INGELHEIM VETMEDICA, INC.
    Inventors: Michael BECK, Jeffrey KNITTEL
  • Publication number: 20100266629
    Abstract: The present invention relates to combination vaccines and methods for treating or preventing diseases or disorders in an animal caused by infection by Bovine Viral Diarrhea Virus (BVDV) Types 1 and 2, Bovine Herpes Virus Type-1 (BHV-1), Bovine Respiratory Syncytial Virus (BRSV), Parainfluenza Virus (PI3), Campylobacter fetus, Leptospira canicola, Leptospira grippotyphosa, Leptospira hardj-prajitno, Leptospira icterohaemmorrhagiae, Leptospira hardjo-bovis and Leptospira pomona by administering to the animal an effective amount of a combination vaccine. The combination vaccine can be a whole or partial cell inactivated or modified live preparation.
    Type: Application
    Filed: June 22, 2010
    Publication date: October 21, 2010
    Applicant: PFIZER INC
    Inventors: Paul J. Dominowski, Michael John Huether, Mark D. Goodyear
  • Patent number: RE44399
    Abstract: The present invention relates to methods for treating or preventing a disease or disorder in an animal caused by infection by Mycoplasma hyopneumoniae (M. hyo) by administering to the animal at approximately three (3) to ten (10) days of age, a single dose of an effective amount of a M. hyo vaccine. The M. hyo vaccine can be a whole or partial cell inactivated or modified live preparation, a subunit vaccine, or a nucleic acid or DNA vaccine. The M. hyo vaccine administered in accordance with the present invention can be synthesized or recombinantly produced.
    Type: Grant
    Filed: March 2, 2012
    Date of Patent: July 30, 2013
    Assignee: Zoetis LLC
    Inventors: Robin Lee Keich, Lisa Grace Sabbadini